Cairn Biosciences is a San Francisco-based biotech company that specializes in discovering new medicines by mapping multiscale cell dynamics. Their proprietary COMPASS discovery platform utilizes innovative simulations of living biology to navigate complex disease biology and unlock exclusive routes to novel targets and drugs, with a focus on overcoming acquired resistance to targeted cancer therapies.
With a diverse and multidisciplinary team of experts in drug discovery, disease biology, engineering, and computation, Cairn Biosciences is pioneering a new drug discovery paradigm. Their team, led by established biopharma leader and serial drug discovery innovator Mary Ludlam, is dedicated to delivering better therapeutics through their expertise in synthetic cell biology, high-throughput microscopy, computational analysis, and more.
Generated from the website